Test Directory

Next Generation Sequencing (NGS) for Myeloid Disorders

Containers - Adult

Red Cap Tube EDTA KE 9ml
Volume Range

10-15ml Peripheral blood or Bone marrow specimen

Additive per Container


Laboratory Site

Crewe Road South
Telephone: 0131 537 1000

Transport arrangements

Blood and bone marrow specimens should ideally arrive within 24 hours of collection (maximum of 48 hours).  Specimens should arrive no later than 3.30pm on Friday.  Samples should be sent to the following address:

Western General Hospital

Haematology/Biochemistry Combined Reception

Immunophenotyping Laboratory

Crewe Road


EH4 2XU​


See also Specimen transportation

Sample storage arrangements

​Samples should be stored at room temperature. See specimen requirements.​

How to request

Please refer to our detailed requestinginstructions.  The HMDS request form can be located here.​ 


Testing may be performed by reflex from immunophenotyping.


​Monday-Friday 9am-5pm

Anticipated turnaround

Results for diagnostic samples should be expected within 30 working days.  See results.

Static information/disclaimer

This test is accredited to ISO 15189:2012

General additional information

Next generation sequencing is performed using ThermoFisher Oncomine Myeloid Research Panel on the Thermofisher Ion GeneStudio S5 instrument.

Next generation sequencing results are reported on APEX and a copy of report is sent by email to requesting clinicians. Please ensure details are included on NGS request form.


A myeloid NGS panel is available to be performed on the following patient categories:

  • Treatment eligible patient with acute myeloid leukaemia

  • Transplant eligible patient with a diagnosis of myelodysplastic syndrome or primary myelofibrosis

  • For differentiation of hypoplastic MDS and aplastic anaemia

  • Atypical myeloproliferative neoplasm (“triple negative” PMF, MDS/MPN overlap)

  • Relapse AML patient to provide therapeutic information

Please specify to which category the patient belongs when requesting.

For details of genes and fusion partners which are available for assessment, please refer to Next Generation Sequencing.

For clinical advice on appropriate investigations and advice for the interpretation of test results, please contact us​.